Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 25, 2011 Brian Orelli	Teva:P&G :: Peanut Butter:Chocolate The generic-drug maker and consumer-products company are forming a joint venture to sell over-the-counter medication, with both companies bringing their strengths to the table.
The Motley Fool August 25, 2010 Brian Orelli	Shares Soar! That'll Help Investors Sleep Better Tonight. Somaxon finds a marketing partner for its insomnia drug.
The Motley Fool February 26, 2009 Robert Steyer	Merck KGaA's Good Chemistry This German conglomerate successfully mixes drugs and chemicals.
The Motley Fool August 25, 2009 Mike Pienciak	Will P&G Ever Turn Around? Will the recently announced sale of its pharmaceutical business to specialty-drugs developer Warner Chilcott mark a turning point for Proctor & Gamble, or just another misstep?
The Motley Fool November 9, 2007 Brian Orelli	P&G Gives Nastech a Bloody Nose Proctor & Gamble ends its partnership with Nastech Pharmaceutical to develop a nasal spray to treat osteoporosis.
The Motley Fool August 3, 2006 Steven Mallas	A Prosperous P&G Procter & Gamble had a great year that was aided by the Gillette acquisition. This equity is a great long-term core holding; if you see it at an even higher yield, do yourself a favor and take a hard look at this stalwart operation.
The Motley Fool January 31, 2011 Andrew Bond	A Consumer Giant That's on the Cutting Edge Procter & Gamble's innovation comes from many sources.
The Motley Fool December 28, 2006 Michael Leibert	Fool on the Street: P&G Still Going Strong Investors who believe that the consumer goods giant can achieve organic sales growth of 4% to 7% over the next few years might consider the current share price to be an attractive entry point to own a stake in an industry leader.
The Motley Fool January 21, 2011 Brian Orelli	Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir.
The Motley Fool November 1, 2005 Nathan Parmelee	A Small Surprise From P&G Proctor & Gamble delivers, just like it promised, releasing first-quarter earnings that were actually a penny ahead of expectations.
The Motley Fool May 3, 2005 Steven Mallas	P&G Cleans Up on Earnings With its latest numbers, Procter & Gamble proves again why it deserves its blue-chip status.
IndustryWeek May 1, 2002 Tim Stevens	Cashing In On Knowledge Patents, trademarks and trade secrets, once locked away and closely guarded, are among chemical companies' best-selling new products...
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool November 22, 2005 Stephen D. Simpson	Diving Into The Dow: The Fifth Five The authors banter about the relative merits and investment opportunities of some the biggest companies in America: McDonald's... Merck... Microsoft... Pfizer... Procter & Gamble...
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool September 24, 2010 Brian Orelli	Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front.
The Motley Fool January 28, 2011 Matt Koppenheffer	Procter & Gamble Shareholders Need Some Cheer Shares of Procter & Gamble take a dip after it announced fourth-quarter results.
Chemistry World March 12, 2007	Akzo Nobel Sells Medicines Business to Schering Plough US drug giant Schering-Plough is to buy Dutch chemical company Akzo Nobel's pharmaceuticals and animal health business, Organon BioSciences, for 11 billion euros.
The Motley Fool November 7, 2005 Jeremy MacNealy	Can Clorox Remove This Stain? Clorox is a solid company in many ways, but it competes with consumer goods rivals and struggles with increased energy-related costs. Investors, take note.
The Motley Fool September 20, 2005 Steven Mallas	P&G Comes Out Clean Procter & Gamble should do fine, even with the effects of Katrina. At some point, lingering lofty fuel prices may cause havoc on the company's bottom line. If it does, you should consider buying on the dips.
Fast Company July 2008 Melanie Warner	P&G's Sustainability Initiatives -- Not So Sustainable The giant wants to sell $20 billion worth of eco-friendly innovations by 2013. But what about those controversial ingredients?
The Motley Fool April 13, 2006 John Reeves	A Foolish Baby Shower: Procter & Gamble Few stocks have performed as well over the long term as Procter & Gamble. Clearly, this company is built to last. Investors, take note.
The Motley Fool September 10, 2008 Brian Orelli	Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies.
The Motley Fool January 29, 2004 Alyce Lomax	All's Wella at P&G Wella's working, but will Procter & Gamble's stake in the German company help P&G take over the world?
Chemistry World December 21, 2015 Phillip Broadwith	Is bigger really better? Something that's often glossed over in the aftermath of a pharmaceutical mega-merger is whether savings actually materialize, and at what cost to the future success of the businesses.
The Motley Fool May 21, 2010 Brian Orelli	Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea.
The Motley Fool January 30, 2009 Colleen Paulson	It's a Big World, P&G Global currency fluctuations eat into Procter & Gamble's quarterly earnings.
BusinessWeek July 12, 2004	At P&G, It's All About Targeting Consumer-product giant Procter & Gamble's global marketing officer explains why its ability to "embrace" the new diversity of media "is really exciting"
The Motley Fool July 16, 2010 Sean Sun	Stock Cheat Sheet: Procter & Gamble If you're new to Procter & Gamble, consider this your cheat sheet to get introduced to the consumer products giant.
Chemistry World May 29, 2012	Solvay opens 200 employee Indian R&D centre The center -- in Savli, Gujarat State -- will focus on high-performance polymers, organic chemistry, nano-composites and green chemistry.
The Motley Fool August 31, 2010 Matt Koppenheffer	How Much Is Procter & Gamble Worth? Is Procter & Gamble's stock on sale?
The Motley Fool July 19, 2010 Eric Bleeker	Procter & Gamble's Tricky Ambitions Can it maintain margins while moving further into value segments?
The Motley Fool October 26, 2010 Matt Koppenheffer	Can Procter & Gamble Defeat the Private Labels? Can P&G's latest marketing push help it reinvigorate sales in its largest market?
The Motley Fool November 9, 2006 Todd Wenning	The Best Blue Chip for 2007: Procter & Gamble Investors, this omnipotent consumer staples firm is the best blue chip in the market.
The Motley Fool February 2, 2005 Tom Taulli	Tyco's Still in Cleanup Mode Ed Breen has done a tremendous job in the Tyco turnaround. But as with all turnarounds, there's still work to be done. Its stock fell $1.63 to $34.51 upon that news. The 52-week high is $36.58.
The Motley Fool April 1, 2004 Bill Mann	P&G Unloads Sunny D Procter & Gamble sells its juice-based drink brand to J.W. Childs.
The Motley Fool May 18, 2010 Brian Orelli	What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout.
The Motley Fool August 3, 2007 Ryan Fuhrmann	Procter & Gamble Leads the Way In its fourth-quarter and full-year earnings conference call, Proctor & Gamble shows why it continues to dominate the global market in consumer goods.
The Motley Fool August 4, 2010 Matt Koppenheffer	Have You Sold Your Procter & Gamble Shares Yet? Procter & Gamble reported earnings that disappointed the market.
HBS Working Knowledge March 20, 2006 Huston & Sakkab	P&G's New Innovation Model Procter & Gamble's assessment of its aging innovation process and the development of connect and develop.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
The Motley Fool January 28, 2011 Luke Timmerman	Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool August 6, 2009 Colleen Paulson	Procter & Gamble Fights the Tide Global currency fluctuations and declining volume hurt P&G's profits in the fourth quarter.
The Motley Fool January 27, 2006 Stephen D. Simpson	P&G Stocks Up on Profits Solid execution continues to be the hallmark of this consumer-goods giant. Investors, take note.
The Motley Fool November 2, 2006 Steven Mallas	P&G Just Peachy Investors, you can count on Procter & Gamble to deliver the earnings goods.
The Motley Fool April 30, 2004 Nathan Slaughter	P&G's Everyday Profits The consumer products giant Proctor & Gamble reports surging sales and earnings.
The Motley Fool October 30, 2009 Mike Pienciak	P&G Inches Forward Slowly, very slowly, Procter & Gamble is crawling out of consumer-staples purgatory. But don't be fooled -- the world's largest consumer products company has a long way to go before it reaches growth nirvana.
IndustryWeek January 1, 2007 Jill Jusko	Consumer Products Companies Best Practices -- A Team Effort Consumer products companies embrace collaboration to speed innovation and product development efforts.
The Motley Fool September 11, 2009 Mike Pienciak	Procter & Gamble Caves In to the Recession The consumer products giant is cutting prices to lure back customers.